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Abstract: Biocompatible and bio-based materials are an appealing resource for the pharmaceutical 
industry. Poly(glycerol-adipate) (PGA) is a biocompatible and biodegradable polymer that can be 
used to produce self-assembled nanoparticles (NPs) able to encapsulate active ingredients, with 
encouraging perspectives for drug delivery purposes. Starch is a versatile, inexpensive, and 
abundant polysaccharide that can be effectively applied as a bio-scaffold for other molecules in 
order to enrich it with new appealing properties. In this work, the combination of PGA NPs and 
starch films proved to be a suitable biopolymeric matrix carrier for the controlled release 
preparation of hydrophobic drugs. Dynamic Light Scattering (DLS) was used to determine the size 
of drug-loaded PGA NPs, while the improvement of the apparent drug water solubility was 
assessed by UV-vis spectroscopy. In vitro biological assays were performed against cancer cell 
lines and bacteria strains to confirm that drug-loaded PGA NPs maintained the effective activity of 
the therapeutic agents. Dye-conjugated PGA was then exploited to track the NP release profile 
during the starch/PGA nanocomposite film digestion, which was assessed using digestion models 
mimicking physiological conditions. The collected data provide a clear indication of the suitability 
of our biodegradable carrier system for oral drug delivery.  
Keywords: starch; nanoparticles; drug delivery; polymer; poly(glycerol-adipate); biomaterial; 
biocompatible; nanocomposites 
 
1. Introduction 
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Nanostructured polymers are finding increasing use in pharmaceutical research for the 
development of drug delivery systems. Nano-delivery systems can be achieved with natural or 
synthetic polymers, however, synthetic polymers often have critical drawbacks, such as a lack of 
biodegradability and biocompatibility, with implications of inflammation and toxicity [1]. In this 
regard, poly(glycerol adipate) (PGA) is a valid synthetic solution. PGA is an enzymatically 
synthesized polymer that has been shown to be a green, biodegradable, and biocompatible 
macromolecule. It has an amphiphilic balance within the repetitive unit that aids with the 
production of self-assembled nanoparticles (NPs) by nanoprecipitation in water [2]. Moreover, the 
PGA suitability for drug delivery carrier development has previously been explored. For example, 
PGA was used as a drug delivery device of indomethacin. In particular, the polymer was grafted 
with the drug producing a novel composite. This grafted PGA could self-assemble into NPs and act 
as a drug “cargo” for a controlled delivery system [2–4]. 
Oral drug delivery systems are an important strategy to achieve more effective formulations, 
especially those concerning poorly bioavailable drugs, such as Biopharmaceutical Classification 
System (BCS) class II compounds, which are defined as highly permeable but poorly aqueous 
soluble molecules [5]. In this case, the role of the carrier systems is to increase the apparent water 
solubility of the drug in order to improve its bioavailability. This process can be limited by an 
earlier instability of the carrier, causing an unwanted drug precipitation in the body fluids before it 
can reach the proper site of absorption [6]. The combination of nanostructured drug carriers with 
polymeric matrices could represent an innovative and effective approach to overcome this 
limitation. 
Interestingly, the NPs produced with PGA show high-stability when embedded in complex 
polymeric semi-crystalline matrices [3]. One example of these matrices is starch, the most abundant 
polysaccharide on the earth [7–9]. Starch is a polymer composed of two macro-molecules: amylose 
and amylopectin. Amylopectin is a much larger branched polymer than amylose and represents 
approximately 75% of starch. Amylose instead is a linear polymer composed by α-(1-4) linked 
glucose units [8,10]. Recently, it was demonstrated that starch is a suitable vector for the transport 
of PGA NPs [3]. It was proposed that starch could trap NPs in its crystalline phase after producing 
the casted films, which should allow a more controlled release of a drug. Furthermore, starch films 
produced with and without NPs stimulated the growth of intestinal cells. 
For all these reasons, we sought to develop a novel oral drug delivery system consisting of 
native barley starch blended with PGA NPs in order to obtain a biocompatible nanocomposite to 
improve the apparent water solubility of drugs. 
Kinase inhibitors (KIs) are a class of drugs whose application in cancer treatment is constantly 
growing. Indeed, 49 KIs have been approved by the FDA over the last 20 years [11,12] and more 
than 2000 clinical trials evaluating these compounds are ongoing [13]. KIs, blocking specific 
enzymatic pathways that are hyper activated in tumors, have paved the way for better tolerated 
and targeted cancer therapies [14]. Although small molecule KIs can generally be orally 
administered [12] with remarkable advantages for patient treatment, they are often affected by a 
poor pharmacokinetic profile. This can lead to variations in plasma concentration, insufficient levels 
of the drug at the site of action, variability in systemic response, and other hardly controllable 
answers that can compromise the efficacy of therapy [15]. For these reasons, many strategies, such 
as the preparation of prodrugs, polymeric NPs, or liposomes, have been already developed or are 
under investigation in order to overcome this KI intrinsic limit [16].  
Schenone et al. have reported a wide library of potent KIs endowed with a 
pyrazolo[3,4-d]pyrimidine scaffold [17,18]. Many of these compounds are active on different cancer 
cell lines, and some also showed activity in in vivo mouse models [19,20]. Among the members of 
this library, compound SI214 (Figure 1a) is a potent Src inhibitor (Ki = 90 nM) and possesses a 
considerable antiproliferative effect on the SH-SY5Y Neuroblastoma cell line (IC50 = 80 nM). Despite 
these promising biological data, SI214 has low solubility in water (0.12 g/mL), which prevents its 
oral administration [21]. It has been successfully demonstrated that solid dispersions of 
pyrazolo[3,4-d]pyrimidine analogous containing an hydrophilic polymer as inert carrier possess an 
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increased apparent water solubility due to enhanced interactions between the hydrophilic 
polymeric chain and the hydrophobic drug scaffold leading. It was further shown that the 
polymer–drug interactions led to the nano-microaggregates of the formulations assembling 
themselves [22]. For this reason, we selected SI214, as a pyrazolo[3,4-d]pyrimidine model, for the 
following study.  
Furthermore, evidence shows that the pyrazolo[3,4-d]pyrimidine nucleus can be a valuable 
scaffold to develop antimicrobial agents [23–25] and thus we additionally evaluated this compound 
against a series of strains of S. aureus and E. coli. 
To further validate our work, we extended the in vitro evaluation to Camptothecin (CPT) 
(Figure 1a), a topoisomerase I inhibitor, whose activity as anticancer agent is confirmed [26] and 
efficacy as antimicrobial drug has been recently investigated [27]. CPT, as with SI214, suffers from 
low solubility in water and, in addition, is characterized by poor stability [28,29]. 
Therefore, in the present study, starch/PGA nanocomposites were characterized for the oral 
drug-delivery of SI214 and CPT molecules as anticancer and antimicrobial agents. A systematic 
study of encapsulation, via solubility enhancement UV-vis evaluation, was performed and showed 
that the NPs increased the apparent solubility in water of the drugs of several order of magnitudes 
compared to the pure drugs. Then, the stability profile of starch-NP nanocomposites was evaluated 
upon exposure to conditions mimicking the human gastrointestinal (GI) environment: the PGA was 
grafted with a fluorophore (Cy5) and the NP release from the matrix starch was monitored in a 
dynamic in vitro model simulating the human digestion. The formulations tuned the release of the 
NPs, demonstrating the feasibility of our novel system as an edible nanocomposite. 
2. Materials and Methods  
2.1. Materials 
All the chemicals used in this work were purchased from Sigma-Aldrich (Saint Louis, MO, 
USA) unless otherwise stated. Altia Industrial (Koskenkorva,Finland) kindly supplied the barley 
starch. Caco-2 human epithelial colorectal adenocarcinoma cells were obtained from the American 
Type Culture Collection (ATCC; Manassas, VA, USA), and were used between passages 30-35 and 
HCT116 colorectal cancer cells were obtained from AMS Biotechnology (Abingdon, UK). S. aureus 
(SA01, SA02) and E. coli (EC07, EC19) bacteria were obtained from AMS Biotechnology (Europe). 
The PrestoBlue cell viability assay was purchased by Thermo Fisher Scientific (Waltham, MA, 
USA). Compound SI214 was synthesized as previously described [21]. CPT was purchased from 
Cambridge Bioscience (Cambridge, UK). 
2.2. Methods 
2.2.1. PGA and Cy5-PGA Synthesis 
PGA was enzymatically synthesized from divinyl adipate and glycerol in tetrahydrofuran 
(THF) at 40–45 °C by a lipase immobilized on acrylic beads (Novozyme 435), as described by 
Sagnelli et al. [3]. PGA-Cy5 (PC) conjugate was synthesized via the direct coupling of amino-Cy5 to 
the free carboxylic end group of the polymer by carbonyldiimidazole mediated reaction. After 
purification via multistep precipitations and dialysis, against a mixture of water and methanol, the 
degree of coupling was assessed by UV-vis measurement.  
2.2.2. PGA NP Preparation and Characterization by Dynamic Light Scattering (DLS) 
PGA NPs were produced by the solvent displacement technique, also called nanoprecipitation 
[30]. We used acetone (2 mL) as an organic solvent to dissolve the polymer and ultrapure water (10 
mL) as a non-solvent system to achieve the NP formation. The PGA polymer (15 mg) dissolved in 
acetone was dropped into the water (1.5 mg/mL PGA in the aqueous medium) under constant 
magnetic stirring (550 rpm) at Room Temperature (RT) (19 °C). The mixture was left overnight in a 
fume hood while being agitated to let evaporate the organic phase. Blue PGA NPs were produced 
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in the same way, but with a 1:5 (w/w) mixture of PC and PGA, in order to reach a total final 
polymer concentration of 1.5 mg/mL in water. Likewise, the drug loaded NPs were obtained with 
the same nanoprecipitation technique, dissolving both the polymers and the drug in the organic 
phase. In this case, the drug was in a 1:5 (w/w) ratio respect to PGA.   
The different formulations in ultrapure water (1.5 mg/mL) were characterized by DLS 
(Zetasizer Nano ZS, Malvern Instruments, Malvern, UK). Measurements in triplicate were used to 
calculate average intensity particle size distributions. 
2.2.3. Casting of Films 
The films were prepared in order to reach a final starch surface density of 10 mg/cm2, taking 
into account the native water content (%w) of starch [3]. The blue PGA NPs were 3% of starch (dry 
weight, d.w.). The starch was suspended in ultrapure water and the mixture was heated under 
magnetic stirring in an oil bath at 95 °C for ≈20 min, until complete starch melting was achieved. 
Then, the solution was rapidly cooled in an ice bath up to a temperature of 50 °C before mixing a 
proper volume of NPs and perform the casting. For the negative control (blank), an equal volume of 
ultrapure water with respect to the NPs suspension was mixed to the 50 °C starch solution. The 
films were prepared by casting in teflon-coated petri dishes and dried at 50 °C in a ventilated oven. 
2.2.4. In vitro Static Digestion of Starch/Blue PGA Nanocomposites 
A simplified static in vitro digestion method was used, as reported by Sagnelli et al. [31]. 
Simulated Salivary Fluid (SSF: 15.1 mM KCl, 13.6 mM NaHCO3, 0.75 mM CaCl2, pH 7), Simulated 
Gastric Fluid (SGF: 6.9 mM KCl, 47.2 mM NaCl, 12.5 mM NaHCO3, 0.075 mM CaCl2, pH 2), and 
Simulated Intestinal Fluid (SIF: 6.8 mM KCl, 38.4 mM NaCl, 85 mM NaHCO3, 0.3 mM CaCl2, pH 7) 
were used to mimic the physio-chemical human gut conditions, and they were freshly prepared 
before use. Starch/blue PGA nanocomposites and plain starch films (negative control) were cut into 
small pieces in order to simulate the oral mastication. A total of 0.5 g (dry weight, d.w.) of chopped 
and SSF at a 1:2 (w:w) ratio was incubated under shaking conditions (170 rpm) at 37 °C for 1 min. 
An equal volume of SGF supplemented with fungal lipase (in SGF 60 IU/mL) and porcine pepsin 
(in SGF 1200 IU/mL) was added to the bolus to mimic the gastric phase (incubation for 30 min, at 37 
°C, at 170 rpm shaking speed). In the intestinal phase, SIF solution with pancreatic α-amylase (in 
SIF 200 IU/mL) as porcine pancreatin 8X (L3126 Sigma-Aldrich) was added at a 1:1 (v:v) ratio with 
respect to the chyme volume, and the samples were incubated for 17 h (37 °C, 170 rpm shaking 
speed). Triplicate aliquots (70 µL) were taken at different time points (0, 30 min, 1 h, 2 h, 17 h) and 
replaced with an equal volume of fresh SIF. The collected aliquots were dropped in 70 µL of 99% 
ethanol and snap frozen in liquid N2 to interrupt the digestion [31]. 
2.2.5. Dynamic Digestion  
A dynamic in vitro model called The Smallest Intestine (TSI) was used, as described by Cieplak 
et al. [32]. Briefly, the TSI allows us to modulate the physiochemical conditions (pH, bile, and 
gastric enzymes) through the human stomach and small intestine (SI), exploiting dialysis to 
simulate absorption and using a consortium of SI bacteria to simulate a healthy ileal microbiota. 
Five stirred batch-like reactors useable in parallel constitute the whole TSI unit, and each reactor 
(with a working volume of 12 mL) mimics one person’s SI. Specifically, the reactors are able to 
simulate the stomach, duodenum, jejunum, and ileum passage under controlled conditions 
(temperature, pH, anaerobic environment). The stomach passage (fasted state, pH = 2) was 
simulated as lined out previously [32] for 30 min using 1 g of nanocomposite (starch/blue PGA 
films or plain starch films as negative control). After 30 min in stomach conditions, the duodenum 
step started (30 min), followed by the jejunum (300 min) and ilium (120 min) passage [32].  
Simulated Salivary Fluid (SSF), simulated gastric fluid (SGF), and simulated intestinal fluid 
(SIF) [30] devoid of sodium bicarbonate were used to mimic the electrolyte composition and 
osmotic pressure occurring in the human GI tract, as reported by Cieplak et al. [32]. The experiment 
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was conducted in fasted state at 37 °C. The TSI reactors were filled with 1.4 mL SSF (PH 7), 2.3 mL 
of SGF (pH 3) and pepsin solution (pepsin activity of 2000 U/mL in the final volume), 1.4 mL of 
water, and 1 g of nanocomposite (starch/blue PGA films or plain starch films as negative controls). 
After 30 min, 4.5 mL of SIF, 10 µL of 0.6 M CaCl2, pancreatic juice as a mixture of SIF and porcine 
pancreatin 8X (trypsin activity of 40 U/mL in the final volume), and the bile solution (4 mM bile 
acids in the final volume) were added to simulate the duodenum. During the duodenal passage, a 
pH steady increment from 6 to 6.8 was achieved. Dialysis cassettes (Slide-A-Lyser G2, 
ThermoScientific) with a cut-off of 10 kDa were used to simulate the absorption of electrolytes, 
small nutrients, and bile during jejunal digestion, and the pH was elevated from 6.8 to 7.2. Fresh SIF 
(pH 7.2) supplemented with SI microbiota (107 CFU/mL in the reactor) was added with a chyme to 
SIF ratio of 50:40 (v/v) to simulate the ileum stage (pH 7.2). During the 7 h digestion, duplicate 
samples (70 µL) were taken at different time points for two biological replicates and the negative 
control (Stomach: 0 min, 30 min; Duodenum: 60 min; Jejunum: 180 min, 300 min; Ileum: 420 min). 
The collected samples were dropped in one volume of 99% ethanol and snap frozen in liquid N2 to 
interrupt the digestion. 
2.2.6. NP Release Profile Evaluation 
Aliquots collected during the static/dynamic digestion experiments were defrosted in ice and 
then centrifuged at 4000 rpm and 4 °C for 10 min. The supernatants were plated in 96 well plates 
and the UV absorbance at 650 nm was recorded. The calibration curve of blue PGA NPs was 
constructed and used to calculate the cumulative percentage release of NPs over time. 
2.2.7. Cell Culture Conditions 
Cells were routinely cultured in a growth medium at 37 °C with 5% CO2 in 75 cm2 culture 
flasks until 70% confluency was achieved. The Caco-2 cell growth medium consisted of Dulbecco's 
Modified Eagle Medium (DMEM) supplied with 10% (v/v) Fetal Bovine Serum (FBS), and 2 mM 
L-glutamine. HCT116 cells were cultured in McCoy’s 5a medium containing 10% (v/v) FBS. 
2.2.8. Cytotoxicity of Study Formulations 
The PrestoBlue cell viability assay (Thermo Fisher Scientific) was performed to assess NP 
cytotoxicity via the measurement of cellular metabolic activity. The Caco-2 cells were seeded at 
1x104 cells/well in 96 well plates and HCT116 cells were seeded at a density of 2 × 104 cells/well. The 
cells were cultured for 24 h prior to assaying. Formulations were applied to cells in a growth 
medium containing 10% (v/v) FBS at NP concentrations of 0.5 mg/mL. Triton X-100 (TX-100) 
applied at 1% (v/v) was used as a cell death (positive) control and a vehicle control containing no 
NPs used as a negative control. After 48 h of exposure, the cells were washed twice with warm PBS 
and 100 µl 10% (v/v) PrestoBlue reagent diluted in a phenol red free medium applied per well for 
60 min. The resulting fluorescence was measured at 560/600 nm (λex/λem). Relative metabolic 
activity was calculated by setting values from the negative control as 100% and positive control 
values as 0% metabolic activity. 
2.2.9. Minimum Inhibitory Concentration (MIC) 
The in vitro antimicrobial activity of study formulations was performed against two strains of 
gram-positive S. aureus (SA01, SA02) and two strains of gram-negative E. coli (EC07, EC19) bacteria. 
The MIC was determined via broth microdilution assay. Formulations were prepared at a 
concentration of 1000 µg/mL in Luria Bertani (LB) broth, and free drug was prepared at a 
concentration of 250 µg/mL in LB broth. An overnight culture was grown from a single colony in 10 
mL LB broth at 37 °C in an incubator at 180 rpm overnight. A subculture was prepared by diluting 
the overnight culture 1:100 and then 1:20 in LB broth and was finally adjusted to 5 × 106 CFU/mL by 
optical density at 600 nm. A two-fold dilution series of 50 µL of test solution was added into 
U-bottom 96 well plates followed by the addition of 50 µL of bacteria subcultures. Positive (without 
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test compound) and negative (without bacteria or test compound) were included in all experiments. 
MIC values were defined as the lowest concentration of test compound that showed no visible 
growth after overnight incubation at 37 °C. 
2.2.10. Molecular Dynamics simulations (MD) 
The models and forcefield parameters for the study of the interactions were developed as 
follows: first, the structures of the drugs and dimers of the polymers (PGA, PGA-Me) were created 
using ChemDraw3D. The structures were submitted to the online Automated Topology Builder 
(ATB) tool [33,34] that provided appropriate parameters for use with the GROMOS54a7 [35,36] 
force-field. The systems were composed by placing a dimer and a single drug molecule in a box and 
solvating the system (SPC water model [37]). After solvation, the atoms were relaxed by 10,000 
steps of EM with the steepest descent algorithm followed by an equilibration via NVT ensembles at 
298 K (V-rescale thermostat) for 100 ps and then in an NPT ensemble at 1 bar (Berendsen barostat). 
Bonds to hydrogen atoms were constrained to allow a time step of 2 fs. All of the MD simulations 
were run with the same barostat and thermostat under PBC. Long-range electrostatics were treated 
with PME [38,39]. 
3. Results and Discussion 
3.1. NPs’ Formation and Drug Water Solubility Enhancement 
PGA, PGA-CTP, and PGA-SI214 NPs were formulated via simple nanoprecipitation technique, 
using acetone as the organic phase. A DLS screening assay and zeta potential analysis were 
performed in order to fully characterize the NPs (Table 1). 
Table 1. Size distribution, polydispersity index, and zeta potential data of the produced 
nanoparticles (NPs). 
 Size (nm) PdI Z-potential (mV) 
PGA 175.0 ± 1.9 0.033 −12.0 ± 0.5   
PGA-SI214 172.3 ± 1.8 0.030 −15.2 ± 0.9 
PGA-CPT 184.1 ± 2.0 0.027 −17.6 ± 0.5  
Both bare and loaded PGA NPs showed comparable sizes (range size: 172.3–184.1 nm), and a 
very narrow size distribution (PdI < 0.033). These data indicated a similar packaging for plain PGA 
and PGA-SI214 or PGA-CPT (Figure 1a) and a good quality of NPs, respectively. Furthermore, the 
negative surface charge of NPs (negative zeta potential), due to the free OH of the PGA, conferred 
NPs stability in an aqueous environment [40–42].  
Analysis of the variation of the absorbance between the free drugs in water and their PGA 
formulation was assessed by UV-vis spectroscopy [22] and revealed an enhancement of the 
apparent water solubility of both compounds after encapsulation (Figure 1b). 
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Figure 1. (a) Poly(glycerol-adipate) (PGA) (above), SI214, and Camptothecin (CPT) (below) 
structures; (b) ΔA% average of the two nano-formulations calculated against the pure drugs in 
water. 
PGA-SI214 exhibited a higher ΔA% than PGA-CPT. This is likely because SI214 is able to form 
more interactions with PGA than CPT, as supported by DLS study that showed a higher contraction 
of the size for the pyrazolo-pyrimidine derivative compared to the alkaloid (size of PGA-SI214 < 
size of PGA-CPT). 
3.2. All Atom Molecular Dynamics (MD) Simulation 
All atom molecular dynamics (MD) simulations are attracting attention in the polymer-based 
drug delivery field as a tool to enlighten the interactions taking place at an atomistic level [43–45]. 
Our 10 ns MD simulations for the interactions between the dimers of PGA and the two drugs were 
used to evaluate the distance between the moieties and the possible formation of hydrogen bonds. 
Multiple H-bond formation was observed in the PGA-SI214 simulation (Figure 2a,b), while no 
H-bonding formation was observed in the PGA-CPT simulation (Figure 2c,d). These preliminary 
computational data can be used to corroborate the different experimental enhanced apparent water 
solubilities of the two drugs when formulated with the polymer (Figure 1b). In fact, as can be seen 
from Figure 1b, SI214 ΔA% improved twofold compared to the CPT, hinting to a better interaction 
between the polymeric chains and the KI drug. 
 
 
 
(a)  (b) 
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Figure 2. (a) The final configuration of the PGA dimer (grey) and the SI214 molecule (green) after a 
10 ns all atom Molecular Dynamics simulation; (b) distance (blue) and H-bonds (orange) between 
PGA and SI214; (c) the final configuration of the PGA dimer (grey) and the CPT molecule (green) 
after a 10 ns all atom Molecular Dynamics simulation; (d) distance (blue) and H-bonds (orange) 
between PGA and CPT. 
3.3. Bioactivity of the Loaded NPs against Cancer Cells and Bacteria 
The biological activity of the loaded NPs dissolved in an aqueous solution was tested against 
two intestinal cancer cell lines (i.e., Caco-2 and HCT116 cells) and different strains of gram-positive 
and gram-negative bacteria. The application of the drug-loaded PGA- NPs to Caco-2 intestinal cells 
induced cell death, as determined by the loss of cellular metabolic activity, confirming the delivery 
of the encapsulated agents (Figure 3a). It can be noted that both formulations elicited similar levels 
of cytotoxicity, with PGA-SI214 and PGA-CPT reducing cell metabolic activity to 72.1% ± 7.5% and 
68.1% ± 1.4%, respectively. 
  
(a) (b) 
Figure 3. In vitro cytotoxicity of study formulations on Caco-2 (a) and HCT116 (b) intestinal 
epithelial cells. Formulations were applied to cells at a polymer concentration of 0.5 mg/mL diluted 
in Dulbecco's Modified Eagle Medium (DMEM) containing 10% Fetal Bovine Serum (FBS) for 48 h. 
A total of 1% (v/v) Triton X-100 (TX-100) was used as the positive cell death control. Caco-2 and 
HCT116 cells were seeded on 96 well plates at a density of 1 × 104 and 2 × 104 cells/well, respectively, 
and were cultured for 24 h prior to assaying. Metabolic activity was assessed using the PrestoBlue 
assay. The data represent mean ± S.D. (n = 3). 
Slightly enhanced results were observed for HCT116 cells. In vitro data demonstrated that 
both SI214 and CPT formulated with PGA were cytotoxic, inducing a reduction of the metabolic 
activity of 56% and 36%, respectively (Figure 3b). The higher activity demonstrated by both 
compounds in HCT116 cells may be explained by the expression of oncogenes in this cell line that 
are absent in Caco-2 cells, such as mutant KRAS and PIK3CA genes [46–48]. These gene mutations 
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may subsequently confer HCT116 cells increased susceptibility to treatment with a Src tyrosine KI 
and CPT [49–51]. 
Then, to evaluate if SI214 and CPT could be developed as antimicrobial agents, we tested 
against 2 strains of gram-positive S. aureus (SA01, SA02) and 2 strains of gram-negative E. coli 
(EC07, EC19) bacteria. The two compounds have been assayed both as free drugs dispersed in 
water and drug-loaded PGA NPs. As can be noted in Table 2, no activity was detected for drugs 
suspended in water, while the same Minimum Inhibitory Concentration (MIC) values have been 
calculated for both encapsulated compounds towards S. aureus and E. coli, respectively.  
Table 2. Minimum Inhibitory Concentration (MIC). 
 SA01 SA02 EC07 EC19 
SI2141 n.d. n.d. n.d. n.d. 
PGA-SI214 500 µg/mL 500 µg/mL 250 µg/mL 250 µg/mL 
CPT1 n.d. n.d. n.d. n.d. 
PGA-CPT 500 µg/mL 500 µg/mL 250 µg/mL 250 µg/mL 
1 For drugs dispersed in water no activity was detected. 
In particular, PGA-SI214 and PGA-CPT were 2-fold more potent against the two strains of E. 
coli than those of S. aureus, suggesting a screening of PGA-drug NPs against a panel of 
gram-negative bacteria as a possible continuation of this work.  
3.4. Film Formation and NPs Entrapment 
The suitability of barley starch film as bio-based coating polymer for PGA NPs has been 
previously reported [3]. Tests performed on Caco-2 cells using film extracts proved the starch/PGA 
nanocomposite biocompatibility. In fact, no cell membrane damage was detected, and the cell 
metabolic activity seemed to be increased by the free starch content of the extracts. 
Prior to the preparation of the films, the stability of PGA NPs was assessed at 50 °C by DLS, to 
ensure NPs integrity during the film drying process. The monitoring of the NPs’ size at 50 °C over 
24 h did not show significant changes in the NP dimension (data not shown), proving the PGA 
NPs’ suitability for the nanocomposite film preparation. Moreover, the PGA NPs stability in the 
starch matrix was previously showed by Sagnelli et al. [3].  
3.5. Blue-NPs’ Release from Film in Different Buffers 
The starch/PGA nanocomposite films were characterized via a static in vitro method 
simulating the physiochemical conditions of the human gut to evaluate the NP release profile over 
time as a cumulative percentage. As shown in Figure 4, because of the mild hydrolysis of the starch 
matrix in both SSF and SGF, only a minimal release of 8.4% was detected at the time of the SIF 
addiction (t0).  
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Figure 4. Release of PGA-Cy5 (PC) conjugate during in vitro static digestion. 
The small intestine represents the major site for absorption [52], and thus the starch matrix 
appears to be a useful bio-scaffold to preserve the integrity of the biodegradable PGA NPs to the 
site of interest, hampering PGA degradation in the oral–gastric tract. Indeed, PGA NPs are 
susceptible to degradation by the different digestive enzymes that cause the polymer breakdown. 
Additionally, PGA NPs are short-lived at the acidic pH of SGF [3,42]. In particular, Swainson et al. 
reported that the acidic pH of SGF caused PGA NPs instability, and an important swelling in terms 
of PGA NP hydrodynamic size was observed in the presence of lipase, suggesting degradation [42]. 
The PGA NP degradability by lipase was further proved by Sagnelli et al., who reported a tenfold 
increment in NP size after a 3 h incubation with lipase with respect to the enzyme-free NP control 
[3]. Undoubtedly, it is necessary to have complete drug retention in stable NPs to ensure that the 
active principle perseveres its solubilized state until reaching the absorption site in the small 
intestine. Drug absorption through the intestine mucous membrane is commonly achieved once the 
polymeric micelles release their active content in the gut environment [5]. In this regard, a biphasic 
NPs release pattern was detected during the simulated intestinal digestion (Figure 4), with an early 
42% burst release of PGA NPs in the first hour. Then, a zero-order-like release phase seemed to take 
place, reaching a total release of 79% after 17 h. The gradual drug release in the small intestine 
fluids from loaded PGA NPs could reasonably take place once NPs were free from the starch 
matrix, as the biodegradability of the PGA NP was extensively shown by Swainson et al. [42] using 
lipase, pancreatin, and other digestive enzymes.  
3.6. Digestion Model of the Edible Film  
To further validate our results, the stability profile of our nanocomposite was evaluated using 
the TSI, a dynamic method that simulates the physicochemical conditions found in the human gut. 
Dynamic models have the advantage over static models to better mimic the physiological changes 
occurring through the different sections of the human GI tract, e.g., the dynamic variation of pH or 
the absorption process. The TSI reported by T. Cieplak et al. [32] is a small volume in vitro model 
working under controlled temperature and anaerobic conditions. The TSI is able to simulate the 
stomach, duodenum, jejunum, and ileum passages (Figure 5) using simulated gastric fluids 
containing digestive enzymes and the addition/absorbtion of bile salts and inoculation with a 
representative gut microbiota consurtium along the process. 
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Figure 5. Flow chart detailing the simulated dynamic digestion by the The Smallest Intestine (TSI) 
model. 
During the gastric phase, the Starch/PGA film was incubated with SSF and SGF containing 
pepsin. The PC absorbance level in this phase was negligible (Figure 6), confirming that the 
nanocomposite was stable in this acidic environment (pH 2). 
  
Figure 6. Release of PC conjugate during in vitro dynamic digestion. 
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At the end of the gastric digestion, the chyme met the SIF, the bile salts, and the pancreatic 
juice. After 30 min of duodenal digestion, the apparent NP concentration reached 0.83 ± 0.31 mg/mL 
(≈ 28% respect to the total NP content of the film) because of the sensitivity of the starch films to the 
intestinal alpha-amylase. A NP concentration of 0.53 ± 0.16 mg/mL (≈ 18% respect to the total NP 
content of the film) was detected in the jejunum after 2 additional hours of digestion, and at the end 
of the jejunal phase the level of NPs was 0.36 ± 0.06 mg/mL (≈ 12% respect to the total NP content of 
the film). The NP concentrations during the jejunal phase were the result of the dynamic balance 
between different processes. On one side, the starch bio-scaffold degrades under the action of 
glycoside hydrolases with a consequent increase in NP level; on the other, the NPs are impaired 
due to the presence of different peptidases, bile salts, and lipase and the subsequent dialyzation of 
the degraded polymer fraction. After 7 h of total digestion, an absorbance related to 0.16 ± 0.04 
mg/mL of NPs was detected in the jejunum, the intestinal site where antimicrobial drugs can start 
to exert their activity. In the future, different cross-linking levels of the starch matrix have to be 
tested to tune the NP release rate in the different GI tracts, in agreement with the activity and the 
site of action/absorption of the encapsulated active agent. 
Interestingly, it should be noted that the data variability decreased for the time points after the 
duodenum phase. This variation in data variability levels could represent a further insight into NP 
breakdown. Indeed, multiple PC degradation by-products may differently result in shifts and shape 
variation in the UV-Vis absorbance peak influencing the data variability, as already reported in 
literature for a comparable dye-PGA conjugate [42]. This phenomenon should be mainly relevant at 
the end of the duodenum phase, as the initial burst releases a multitude of PC sub-products, which 
are produced by NP degradation and retained in the duodenum. Only after reaching the jujenum 
were the PC sub-products dialyzed, limiting their influence on the absorbance behavior. 
The ability of the starch bio-scaffold to avoid the NP impairment in the gastric tract, despite 
the acidic pH and the protease activity, was herein demonstrated. Our nanocomposite system can 
so improve the bioavailability of class II therapeutic agents, avoiding their precipitation in the GI 
fluids and allowing their progressive release in the intestinal environment. 
4. Conclusions 
In this study, we developed PGA/starch nanocomposites as bio-polymeric matrix carriers for 
the controlled release of hydrophobic drugs. In particular, the polymeric formulations of two drugs 
(i.e., SI214 and CPT) with low solubility in water in their native form have been tested against 
different cancer and bacterial cell lines after dissolution in an aqueous medium. Interestingly, 
PGA-SI214 and PGA-CPT showed a certain activity as both antineoplastic and antibacterial drugs. 
This efficacy can be attributed to the enhanced apparent water solubility of formulated drugs 
compared to drugs alone, as confirmed by UV-vis spectroscopy analysis. PGA NPs were 
subsequently embedded in starch films to tune the release of the NPs. Indeed, the evidence shows 
that in vivo NP release is quite difficult to regulate. The starch matrix preserved the integrity of the 
biodegradable PGA NPs until the site of interest, hampering PGA degradation in the oral–gastric 
tract. This behavior has been studied by means of static/dynamic in vitro digestion models. Overall, 
we developed an innovative drug delivery system suitable for oral administration. Moving forward 
from this proof-of-concept study, it would be interesting to next explore the high-throughput 
screening of a panel of compounds to identify potent anticancer and/or antibacterial drugs in cell 
assays, with in an vivo evaluation of the most promising inhibitors in the PGA/starch bio-polymeric 
matrix. 
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